Background: This study (VERxVE) compared the efficacy and safety of the new nevirapine extended-release (NVP XR) formulation dosed once daily with NVP immediate release (IR) twice daily in treatment-naive patients. Methods: Randomized, double-blind, double-dummy, parallel group study of HIV-1-infected adult patients with baseline viral load (VL) ≥1,000 copies/ml and CD4 + T-cell count of >50-<400 (males) and >50-<250 cells/mm 3 (females). Patients stratified by baseline VL (≤100,000/>100,000 copies/ml) were randomized 1:1 to NVP XR 400 mg once daily (plus placebo) or NVP IR 200 mg twice daily (plus placebo), both combined with tenofovir disoproxil fumarate (TDF) 300 mg and emtricitabine 200 mg once daily. Primary endpoint was sustained virological response (<50 copies/ml) through week 48 using the time to loss of virological response algorithm. Non-inferiority of NVP XR to NVP IR was tested using Cochran's statistic incorporating baseline VL stratum with pre-specified, non-inferiority margin of -10%. 
Introduction
regimens are recommended as alternative regimens in therapy-naive patients with CD4 + T-cell counts below those quoted above [2, 3] .
In several non-randomized observational cohort studies, virological and immunological response was reported to be more favourable with EFV than with NVP [4, 5] . The 2NN open-label study compared these two NNRTIs in terms of efficacy and safety. NVP and EFV provided comparable efficacy, although formal non-inferiority criteria within the 10% limit were not met by NVP. Overall, there were no significant differences in clinical adverse events (AEs) between the single NNRTI regimens. However, there were significantly more hepatobiliary abnormalities with NVP than EFV [6] . It is well known that severe skin reactions and hepatotoxicity are the most important side effects of treatment with NVP [7] .
The ARTEN study, an open-label randomized study, compared the efficacy and tolerability of NVP to the new generation protease inhibitor therapy, atazanavir/ ritonavir (ATZ/r), in ART-naive HIV-1 patients and was powered to show non-inferiority [8] . The authors found that NVP, compared with ATZ/r, was noninferior in terms of antiviral efficacy with a favourable lipid profile. The incidence of serious AEs (SAEs) for NVP and ATZ/r was similar, but there were more discontinuations due to AEs with NVP [8] . In the randomized OCTANE trial of 500 treatment-naive African women with CD4 + T-cell counts <200/mm 3 , NVP was virologically as effective as lopinavir/ritonavir (each with fixed-dose TDF/emtricitabine [TDF/FTC]) [9] .
NVP has a well-characterized efficacy, safety and tolerability profile [10] [11] [12] and is currently prescribed as 200 mg once daily for the first 14 days of treatment and subsequently 200 mg twice daily. The ability to take NVP once daily would allow dosing symmetry with once-daily preferred nucleos(t)ides, potentially increasing compliance and thus efficacy of this triple therapy regimen. Consequently, a programme to develop an extended-release formulation of NVP (NVP XR) for once-daily administration was initiated in 2004. The adopted strategy was to develop an NVP XR formulation that provided reduced NVP exposure, with a lower NVP maximum plasma concentration (C max ) than the twice-daily formulation, while maintaining adequate steady-state (ss) trough drug levels (C min, ss ) , as well as the efficacy profile of the original formulation.
In the 2NN study, baseline-adjusted virological response was compared with patients' projected NVP C min, ss by quartiles. In treatment-adherent patients, there was no significant decrease in response seen in C min, ss groups down to the lowest quartile (that is, at least down to 2.3 µg/ml) suggesting a possible threshold within this quartile. In addition, no loss of efficacy was observed when C min, ss was maintained at a level above a lowest limit of 1 µg/ml. No observed relationship was revealed between virological response and projected NVP C min, ss for adherent patients [6] . Based on the findings of the 2NN study, the target pharmacokinetic profile of the NVP XR formulation was a median (±sd) C min, ss of 3 µg/ml (±0.5), which is >15-fold higher than the 95% inhibitory concentration of 710 nM for wildtype virus [13] and with a C max, s /C min, ss ratio <1.5. Such a NVP XR formulation was expected to result in at least comparable efficacy and safety to NVP IR twice daily, as described previously [14, 15] .
A clinical development programme has tested and verified the pharmacokinetic characteristics of a number of different NVP XR formulations. Of these, one was selected for further development [14, 15] . In the present study, efficacy and safety of the new NVP XR formulation (400 mg once daily) was compared with NVP IR (200 mg twice daily) in ART-naive patients, over 48 weeks of treatment (the primary endpoint). Both formulations of NVP were administered in combination with fixed-dose TDF/FTC in a study population with the specific CD4 + T-cell count ranges for males and females, as recommended for NVP treatment [16] [17] [18] . The trial is ongoing and data for up to a planned maximum duration of 144 weeks will be collected.
Methods

Study design and patients
Patients provided written consent and the trial was conducted in accordance with good clinical practice and the ethical principles of the declaration of Helsinki (1996 version). Trial protocol, amendments, informed consent and subject information were reviewed by the local institutional review board or an independent ethics committee. This is a multinational, multicentre, randomized, double-blind, double-dummy, active controlled trial that evaluates the antiviral efficacy and safety of NVP XR 400 mg once daily in comparison with NVP IR 200 mg twice daily, both in combination with TDF/ FTC in adult, ART-naive, HIV-1-infected patients. Adult patients (≥18 years old) with viral load (VL) ≥1,000 copies/ml and CD4 + T-cell count >50-<400 cells/mm 3 for males and >50-<250 cells/mm 3 for females, at screening, were entered. Patients with CD4 + T-cell count ≤50 cells/ mm 3 were excluded. As these patients are more severely immunocompromised with a greater risk of mortality [19] , it was felt they were not suitable, for ethical reasons, to be entered into the non-inferiority, pharmacokinetic VERxVE study, which is planned to last 3 years. Patients underwent genotypic resistance testing at screening and those with resistance to NNRTIs, TDF, FTC or lamivudine (3TC), were excluded. Eligible patients were treated with NVP IR 200 mg once daily during a 14 day lead-in period, and then stratified by VL at baseline (≤100,000/>100,000 copies/ml) and randomized 1:1 within each stratum to NVP XR 400 mg once daily (plus placebo) or NVP IR 200 mg twice daily (plus placebo), both combined with TDF 300 mg plus FTC 200 mg once daily for treatment of at least 48 weeks, in a study of planned duration of 144 weeks.
The primary endpoint was sustained virological response through week 48, defined as two consecutive measurements of VL<50 copies/ml at least 2 weeks apart, and with no subsequent viral rebound or change in ART during this period, according to the FDA's time to loss of virological response (TLOVR) algorithm [20] . Virological rebound was defined as two consecutive measurements of VL ≥50 copies/ml, at least 2 weeks apart, after a virological response.
The key secondary endpoint was TLOVR, defined as time between the start of the lead-in period and last VL <50 copies/ml in an initial virological responder prior to week 48, but with subsequent virological rebound before the patient completed 48 weeks of treatment [20] . Other secondary endpoints included CD4 + T-cell count at week 48 and emergent resistance. Laboratory parameters of interest, including haematological assessments, liver enzymes, lipid compositions and glucose levels, were also measured.
Viral load assay methodology
Plasma samples were obtained at every visit for laboratory analyses and VL was measured by Covance Laboratory Services. VL was routinely measured using the Roche Cobas ® TaqMan assay, which was subsequently shown to perform differently to the Roche Cobas ® Amplicor Ultrasensitive HIV-1 Test, around the lower limit of quantification of 50 copies/ml. Data suggested that in the low VL range, particularly in the critical range of 48-200 copies/ml, the TaqMan assay may report a higher frequency of results greater than the limit of detection (48 copies/ml) compared with the Amplicor Test [21] . Since the trial was initially designed based on characteristics of Amplicor, this was used to reassay the following specimens: all week 48 specimens and all specimens with TaqMan results of ≤200 copies/ml at weeks 24, 32 and 40.
Plasma NVP measurement
Plasma trough concentrations of NVP were assessed at each visit for all patients using a validated method of tandem mass spectrometry (LC-MS/MS) [22, 23] .
Tolerability
AEs were recorded; NVP-specific AEs, such as rash and hepatic impairment, were collected and prospectively recorded on specifically developed case report forms. Hepatic events were recorded for all patients who developed clinical hepatitis or experienced Division of AIDS (DAIDS) Grade 3 or 4 transaminase increase (which were not attributed to an infectious agent or any other cause) while taking study medication.
Genotyping
All genotypic testing was conducted by Monogram Biosciences (South San Francisco, CA, USA) using their commercially available GeneSeq HIV. Resistance to antiviral drugs (including Etravirine [ETR]) was based on the Monogram algorithm [24] . The genotyped patients were classified into four groups based on the data available at week 48: 48-week responders; discontinued treatment for reasons other than efficacy; partial response -achieved a ≥1 log 10 VL decline from baseline, but never achieved a VL nadir of <400 copies/ml; or rebounders -achieved a VL nadir of <400 copies/ml with subsequent VL increase to >500 copies/ml.
Compliance
Treatment compliance was measured by the return of all unused medications at each study visit by patients. Pill count was performed at each visit and compliance calculated as the actual number of pills taken divided by the number of pills that should have been taken.
Statistical analyses
The planned sample size of n=479 per group had 90% power in order to detect non-inferiority of NVP XR to NVP IR with one-sided α=0.025, assuming that the expected difference of proportions of virological responders between two treatment groups is 0, with the proportion being 65% in both groups, based on previous observations [6] . The primary analysis was the non-inferiority test of NVP XR to NVP IR with regard to the proportion of virological responders at week 48 according to the FDA's TLOVR algorithm and as specified by the FDA guidance [20] . The noninferiority test involved constructing a two-sided 95% CI for an adjusted difference of the proportions of virological responders at week 48 in the NVP XR and NVP IR treatment groups. The adjusted treatment difference and corresponding variance were calculated based on Cochran's statistic [25] incorporating baseline VL stratum with continuity correction for variance calculation. All patients who took at least one dose of study medication were included in the analysis. Non-inferiority of NVP XR to NVP IR in terms of efficacy was established if the lower bound of the CI was >-10%. The secondary endpoints of TLOVR and time to new AIDS or AIDS-related progression event or death, were analysed using the Cox proportional hazard model to estimate hazard ratio and 95% CI for NVP XR versus NVP IR treatment with baseline VL stratum variable. Safety parameters were analysed descriptively. SNAPSHOT analysis was also used to analyse the primary endpoint, as a key secondary analysis. In this approach, patients with VL <50 copies/ml in the week 48 ±4 window (that is, between day 309 and day 364) were defined as virological responders and patients discontinuing prior to day 309, or with VL ≥50 copies/ml or missing VL in the week 48 window, were considered as failures.
Results
Patient demographics and trial drug exposure
In total, 1,626 patients were screened and 1,068 received lead-in NVP constituting the treated set. A total of 55 of these patients discontinued during the lead-in phase, resulting in 1,013 patients being randomized, of whom 1,011 were treated (505 with NVP XR and 506 with NVP IR) and this constituted the full analysis set. The full breakdown of the reason for not entering patients is given in Figure 1 . Ineligibility due to inclusion/exclusion criteria was the main reason for not entering screened patients (467/558). The most common inclusion and exclusion criteria not met included: 213 patients with higher or lower than eligible CD4
+ T-cell cell counts, 108 with active hepatitis B or C, 69 had increased laboratory values of DAIDS toxicity greater than Grade 2, 57 were already resistant to NNRTIs or either one of the components of Truvada ® or lamivudine, and 37 had low HIV-1 VL<1,000 copies/ml. It should be noted that patients could have multiple inclusion/exclusion failure reasons ( Figure 1 ). Overall, baseline demographic data were well matched between non-randomized and randomized patients, and were also similar for the NVP XR and NVP IR treatment groups ( In addition to the TLOVR algorithm, a SNAPSHOT method was used to analyse both Amplicor-corrected and TaqMan-only profiles. The SNAPSHOT results are consistent with those of TLOVR algorithm (Table 2) .
Subgroup analysis of primary endpoint
Subgroup analysis showed that patients with baseline VL≤100,000 copies/ml tended to have a higher response proportion for NVP XR No relationship was noted between the primary endpoint and other baseline characteristics such as HIV-1 subtype or CDC class (Table 3) .
Secondary endpoints
Key secondary endpoint TLOVR Based on the Kaplan-Meier curves for TLOVR ( Figure 2) , the proportion of patients without loss of virological response was greater for NVP XR than NVP IR up to pre-specified week 72. The risk for losing virological response for the NVP XR group was 80% of that for the NVP IR group, although the difference was not statistically significant: hazard ratio =0.80 (95% CI 0.63-1.02). (22/31) occurred at or prior to week 16, although only 6 had achieved full suppression of VL<50 copies/ml. By contrast, 6 of the 9 late rebounders (after week 16) had achieved full suppression.
Change from baseline in CD4 + T-cells
NNRTIs and NRTIs mutations
Resistance to the drugs in the treatment regimens developed with the same pattern for NVP XR and NVP IR treatments. Overall 36/86 patients (42%) did not have NVP-resistant virus at virological failure. All of the remaining 50/86 patients (58%) were resistant to NVP. The most frequent emergent NNRTI mutation detected was Y181C. This was also the most frequently detected NVP mutation being present in 38 patients. The frequency and type of NNRTI cross-drug resistance for these 86 patients is shown in Table 4 .
A total of 42/86 (48.8%) patients showed no resistance to any NRTI, consisting of 15/32 (46.9%) in the NVP XR arm and 27/54 (50.0%) in the NVP IR arm. The most common emergent NRTI mutations detected were M184V/I in 38/86 patients (44.2%). Of these, 16/86 had M184V, 12/86 had M184I, with a further 10 having a mixture of at least two of I, M and V. Furthermore, K65R/N mutations were detected in 14/86 patients (16.3%; Table 4 ).
Compliance
Overall mean compliance rate was 98.3% (composed of 99.0% for NVP XR and 97.6% for NVP IR treatment groups). This was based on pill count data from 982 patients who received randomized medication, composed of 492 patients receiving NVP XR and 490 patients receiving NVP IR. Of the remaining 29 patients without pill count data, 27 discontinued before week 4 (visit 4).
Laboratory analyses and abnormalities
With the exception of creatine kinase, serum phosphate and alanine aminotransferase (ALT), Grade 3 or 4 laboratory abnormalities were observed in <5% of patients. The number of patients with Grade 3 and 4 abnormalities for creatine kinase were 17 (3.4%) and 14 (2.8%) for NVP XR, respectively, and 14 (2.8%) and 13 (2.6%) for NVP IR, respectively. Similarly, the number of patients with Grade 3 and 4 serum phosphate abnormalities were 28 (5.5%) and 0 (0%) for NVP XR, respectively, and 25 (4.9%) and 1 (0.2%) for NVP IR, respectively. The largest difference between the two treatment groups was for ALT, where 24 patients (4.8%) in the NVP XR group had Grade 3 or 4 abnormalities compared with 36 patients (7.1%) in the NVP IR group. The cumulative probability of patients experiencing Grade 3 or 4 ALT or aspartate aminotransferase abnormalities suggests that, for both treatment groups, these mainly occurred during the first 4 weeks of treatment.
For all analytes investigated, the median changes from baseline to the last value on treatment were similar for both treatment groups, with small changes in individual values.
Pharmacokinetic parameters
All geometric mean C min, ss NVP concentrations exceeded 3 µg/ml and were stable for both formulations during the reported 48 week period of the 144-week study (results not shown). In an intensive pharmacokinetic substudy of patients (n=24 in the NVP XR arm and n=25 in the NVP IR arm), ss plasma concentrations showed that the overall drug exposure (AUC 0-24, ss , C max, ss ) of NVP XR was lower compared with NVP IR. A lower C max, ss is expected for NVP XR and amounted to 31% lower than for NVP IR. The peak-to-trough 
Discontinuations, tolerability and safety
Lead-in phase During the 14 day lead-in phase, 1,068 patients were given NVP IR 200 mg once daily. In total, there were 55 discontinuations during this period, of which 38 (69.1%) were due to an AE -mostly rash (see below). Eleven discontinuations (20%) were due to an SAE: 7/55 (12.7%) relating to skin and subcutaneous tissue, 3/55 (5.5%) hepatic events and 1/55 (1.8%) infection/external parasitic infestation. There were no deaths in the lead-in phase. Of those patients who were randomized in the lead-in phase, 422/1,013 (41.7%) experienced AEs, with 9/1,013 (0.9%) patients having a SAE. One patient in the randomized lead-in phase experienced a DAIDS Grade 4 AE, which was rash (Table 5) .
Randomized phase
In the randomized treatment period, 32/505 (6.3%) patients in the NVP XR group and 45/506 (8.9%) patients in the NVP IR group prematurely discontinued due to an AE. Rash was the most commonly cited AE for discontinuation, with 9/505 (1.8%) patients in the NVP XR group and 12/506 (2.4%) patients in the NVP IR group. Similar rates of both AEs and SAEs were observed among patients receiving NVP XR and NVP IR (Table 5) . A total of 73 (14.5%) patients in the NVP XR group had a DAIDS Grade 3 or 4 AE compared with 91 (18.0%) of those taking NVP IR, with 25 (5.0%) and 35 (6.9%), respectively, considered to be study drug related (Table 5 ). Sixteen (3.2%) and 23 (4.5%) patients in the NVP XR and NVP IR groups, respectively, experienced DAIDS Grade 4 AEs, of which 6 (1.2%) and 10 (2.0%) were considered to be study drug related.
Incidence of rash
Rash of all types, regardless of drug relatedness, was the most commonly reported AE in non-randomized patients during the lead-in phase (31/55 [56.4%] patients). These were composed of 4 patients (7.3%) with rashes rated as Grade 1, 16 (29.1%) as Grade 2, 10 (18.2%) as Grade 3 and 1 (1.8%) as Grade 4. All patients with Grade 3 or 4 rash were discontinued and follow-up information is unavailable. Two patients developed Stevens-Johnson Syndrome (SJS) during the lead-in phase, one was judged to be Grade 3 and one to be Grade 4 by the investigators. Both instances of SJS were considered related to study medication and both resulted in hospitalization; these patients were not randomized. Rash (of all types) occurred in 10% (101/1,011) of randomized patients: 53/505 (10.5%) in the NVP XR group and 48/506 (9.5%) in the NVP IR group. A total of 29/505 (5.7%) and 25/506 (4.9%) in the NVP XR and NVP IR groups, respectively, were considered to be treatment-related. The majority of patients had Grade 1 or 2 rashes of mild or moderate intensity, which developed during the first 4 weeks of study medication dosing, with 32/505 (6.3%) Grade 1 and 18/505 (3.6%) Grade 2 for NVP XR and 33/506 (6.5%) Grade 1 and 12/506 (2.4%) Grade 2 for NVP IR. However, 3 (0.6%) patients in both the NVP XR and NVP IR groups had Grade 3 rashes. SJS developed in 3 patients in the NVP IR group, 2 being judged to be Grade 3 and 1 as Grade 4 by the investigators. There were no instances of SJS or Grade 4 rashes reported in the randomized patients receiving NVP XR.
Hepatic events
Hepatic events were reported in 5/1,068 (0.5%) patients during the lead-in phase, and 3 of these patients were not randomized. These three patients had multiple symptoms specific for hepatitis and reported hypersensitivity reactions. No patients experienced asymptomatic transaminase increases. During randomized treatment, hepatic events were reported in 74/1,011 (7.3%) patients, 22 of whom were symptomatic. Hepatic events were reported in 28/505 (5.5%) versus 46/506 (9.1%) patients in the NVP XR and NVP IR treatment groups, respectively. A total of 8/505 (1.6%) patients receiving NVP XR exhibited symptoms of hepatitis compared with 12/506 (2.4%) in the NVP IR group. Non-specific symptoms, which could be associated with a hepatic event, were observed in 10/505 (2.0%) patients receiving NVP XR compared with 20/506 (4.0%) of NVP IR patients.
Patients randomized to NVP IR were 71% (odds ratio [OR] 1.71, 95% CI 1.05-2.79) more likely to have any hepatic event than patients randomized to NVP XR with a nearly identical effect size seen when looking at only symptomatic hepatic events (OR 1.77, 95% CI 0.74-4.28). Additionally, symptomatic hepatic events were observed less frequently in the NVP XR treatment group, 14/505 (2.8%), compared with the NVP IR treatment group, 22/506 (4.3%).
In the randomized population, women receiving NVP IR were approximately twice as likely as men to have any of the three categories of events (ORs 2.19, 2.27, and 2.03 for hepatic events, symptomatic events, and Grade 3/4 transaminase increases, respectively). This gender effect was only observed in the NVP IR group.
Deaths
There were a total of 10 deaths up to the 48 week treatment database lock. Of these, four occurred during screening: one from pseudomyxoma peritonei, one from haematophagic syndrome, one from meningitis and one from tuberculosis. There were no deaths during the lead-in phase. Six deaths occurred after starting study medication: one in the NVP XR group and five in the NVP IR group. One patient died of atherosclerosis/hypertension, one of tuberculosis (meningitis), two of sepsis (not in patients with severe skin rash), one of myocardial infarction and one of respiratory alkalosis -this patient had been diagnosed with pulmonary hypertension at screening and developed a fatal case of respiratory alkalosis after study medication was stopped. No fatalities were considered to be related to study medication by the investigators.
Discussion
This trial demonstrated, through the analyses of the primary endpoint, the non-inferior efficacy (using the pre-specified -10% margin) of the NVP 400 mg oncedaily XR formulation compared with the currently available NVP IR 200 mg twice-daily formulation.
No relationship was observed between the primary endpoint and age, gender, race or geographical region (data not shown), but those with lower baseline VL (≤100,000 copies/ml) had a higher proportion of sustained virological response at week 48 than the higher stratum (>100,000 copies/ml) regardless of treatment group. The rates of sustained virological response observed with NVP XR compared with NVP IR when patients were stratified by baseline VL (73.2% versus 70.9%, respectively, for the higher baseline VL group and 85.9% versus 79.2, respectively, for the lower VL group) indicate that the XR formulation is as effective as the IR formulation across a similar range of patients in terms of VL. Importantly, no relationship was noted between the primary endpoint and other baseline characteristics, such as HIV-1 subtype or CDC class (Table 3) . It should be noted that this trial had strict CD4 + T-cell eligibility criteria as per recommended guidelines for NVP in treatment-naive patients. The equivalence of the two formulations is further supported by the observation that there were no meaningful differences between the two treatment groups for any of the other secondary endpoints.
The high virological response observed in this study is in contrast to the findings of two small-scale studies, which have reported early virological failure with NVP IR once-daily regimens combined with TDF+3TC [26] and with NVP twice daily with TDF+FTC [27] . The ARTEN study, using the same treatment regimen (NVP IR with TDF+FTC) also showed high rates of virological response, indicating that this association can be used for treatment of HIV-1-infected patients [8] . It should be noted that, in spite of the double-blind, double-dummy design, compliance was high for both regimens in the present trial. Additionally, it is worth remarking that 55 out of 1,068 patients (5%) discontinued during the lead-in phase and that these would have been counted as treatment failures in both the lead-in and randomized study phases. However, the trial design was discussed with regulatory agencies and it was agreed that the scientific question to be addressed, in as controlled a manner as possible, was how the safety and efficacy of NVP XR once daily compared with NVP IR twice daily after a common lead-in phase of NVP IR once daily. Data from patients who discontinued during the lead-in phase cannot provide useful information about this question. This approach avoided having safety issues during the lead-in phase being confused with those that emerged after the start of NVP XR or NVP IR twice-daily treatment. It also avoided random imbalances in lead-in phase discontinuation or compliance complicating the comparisons of NVP XR and NVP IR twice daily
In terms of resistance development, the observed mutations that emerged in patients experiencing virological failure were predominantly those that would be expected with a NVP-based regimen. However, several of the International AIDS Society list of NNRTI mutations [28] were found not to affect clinical response to NVP even though they are associated with resistance to ETR. In particular, V90I was selected in 3 cases as well as being present at baseline in 32 patients, and there was no evidence that mutations at codon 179 influenced response to NVP.
NVP XR 400 mg once daily was shown to have a tolerability and AE profile similar to that of NVP IR 200 mg twice daily, although with a trend towards fewer AEs. Overall, the safety and tolerability findings of the trial were similar to prior experience with NVP. Rash and hepatic impairment are considered to be the two most important AEs associated with NVP. Rates of rash were similar for the two treatment groups and were predominantly Grade 1 or 2. There were no instances of Grade 4 rash or SJS with NVP XR. Occurrence of hepatic events was similar for both treatment groups, although with numerically less events compared with NVP XR. The reason for this is not clear. The majority of hepatic events took place during the first 6 weeks of NVP exposure. This study shows that the two formulations exhibit similar lipid profiles.
Another large trial is currently on-going with NVP XR. TRANxITION is an open-label, randomized trial in 443 adult patients with HIV-1 who were virologically suppressed (VL<50 copies/ml) with a regimen of NVP IR 200 mg twice daily and fixed-dose NRTI combination of 3TC/ABC, TDF/FTC or 3TC/AZT. These patients were randomized to be switched to NVP XR 400 mg once daily (n=295) or to remain on NVP IR twice daily (n=148). Initial results indicate that switching to the XR formulation resulted in continued, noninferior virological suppression at week 24 and week 48 with similar rates of moderate and severe AEs and SAEs [29, 30] .
In conclusion, the new once-daily formulation of NVP XR 400 mg once daily was non-inferior to NVP IR 200 mg twice daily with regard to efficacy and was similar with regard to tolerability and safety profiles. There was a trend towards improved efficacy and tolerability with NVP XR once daily compared with NVP IR twice daily after 48 weeks of treatment. This trial is ongoing, with planned maximum duration of 144 weeks. The results to week 48 show that the NVP XR formulation has the potential to provide an efficacious and convenient component of a once-daily ART regimen.
